|
Jackie Papkoff, PhD joined CFD Therapeutics upon formation to serve as Executive Vice President of Therapeutics and Chief Scientific Officer. Prior to the spin-out of CFD she worked at diaDexus for 4 years, initially serving as Vice President of Discovery responsible for target discovery, validation and reagent production activities for the diagnostic and therapeutic pipelines and subsequently as Executive Vice President of diaDexus’ therapeutic antibody program for cancer. Jackie joined diaDexus from the Aventis Cambridge Genomics Center (previously Hoechst-Ariad Genomics Center), where she served first as Vice President of Cell Biology and Genetics and then as Head of Genomics Platform Technologies. Prior to her tenure with Aventis, Jackie was Director of Molecular Oncology for Megabios Corporation and before that was a Senior Scientist in Sugen Inc.’s Department of Cellular Biochemistry. She also held several research scientist positions at Syntex Corporation. Jackie was a Consulting Professor of Cancer Biology with Stanford University for over 10 years and served for 3 years (2003-2005) as an advisory council member and Vice Chair for the California Breast Cancer Research Program. She received her B.A. in Biology from the University of California, Santa Cruz, a Ph.D. in Biology at the Salk Institute from the University of California, San Diego and completed postdoctoral research at Stanford University and the University of California, San Francisco. | 